Acumen Pharmaceuticals Inc (NASDAQ: ABOS) has experienced a decline in its stock price by -7.09 compared to its previous closing price of 1.27. However, the company has seen a fall of -3.28% in its stock price over the last five trading days. globenewswire.com reported 2025-03-20 that NEWTON, Mass., March 20, 2025 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report fourth quarter and year-end 2024 financial results on Thursday, March 27, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
Is It Worth Investing in Acumen Pharmaceuticals Inc (NASDAQ: ABOS) Right Now?
Additionally, the 36-month beta value for ABOS is 0.02. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ABOS is 43.92M and currently, short sellers hold a 4.09% ratio of that float. The average trading volume of ABOS on March 21, 2025 was 293.19K shares.
ABOS’s Market Performance
ABOS stock saw a decrease of -3.28% in the past week, with a monthly decline of -15.71% and a quarterly a decrease of -40.10%. The volatility ratio for the week is 10.43%, and the volatility levels for the last 30 days are 7.74% for Acumen Pharmaceuticals Inc (ABOS). The simple moving average for the past 20 days is -6.57% for ABOS’s stock, with a -47.80% simple moving average for the past 200 days.
Analysts’ Opinion of ABOS
Many brokerage firms have already submitted their reports for ABOS stocks, with Citigroup repeating the rating for ABOS by listing it as a “Buy.” The predicted price for ABOS in the upcoming period, according to Citigroup is $7 based on the research report published on July 26, 2024 of the previous year 2024.
Deutsche Bank, on the other hand, stated in their research note that they expect to see ABOS reach a price target of $8. The rating they have provided for ABOS stocks is “Buy” according to the report published on December 12th, 2023.
BofA Securities gave a rating of “Buy” to ABOS, setting the target price at $14 in the report published on July 20th of the previous year.
ABOS Trading at -17.82% from the 50-Day Moving Average
After a stumble in the market that brought ABOS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.36% of loss for the given period.
Volatility was left at 7.74%, however, over the last 30 days, the volatility rate increased by 10.43%, as shares sank -14.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -36.22% lower at present.
During the last 5 trading sessions, ABOS fell by -3.28%, which changed the moving average for the period of 200-days by -59.86% in comparison to the 20-day moving average, which settled at $1.2630. In addition, Acumen Pharmaceuticals Inc saw -31.40% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABOS starting from Zuga Matt, who sale 28,902 shares at the price of $1.72 back on Jan 23 ’25. After this action, Zuga Matt now owns 231,744 shares of Acumen Pharmaceuticals Inc, valued at $49,633 using the latest closing price.
Zuga Matt, the CFO & Chief Business Officer of Acumen Pharmaceuticals Inc, sale 4,364 shares at $1.60 during a trade that took place back on Jan 21 ’25, which means that Zuga Matt is holding 260,646 shares at $6,986 based on the most recent closing price.
Stock Fundamentals for ABOS
Current profitability levels for the company are sitting at:
- -320.37 for the present operating margin
- 0.56 for the gross margin
The net margin for Acumen Pharmaceuticals Inc stands at -281.63. The total capital return value is set at -0.38. Equity return is now at value -32.83, with -29.52 for asset returns.
Based on Acumen Pharmaceuticals Inc (ABOS), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -2.24. The debt to equity ratio resting at 0.14. The interest coverage ratio of the stock is -25.72.
Currently, EBITDA for the company is -51.61 million with net debt to EBITDA at 0.04. When we switch over and look at the enterprise to sales, we see a ratio of 233.44. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.43.
Conclusion
In conclusion, Acumen Pharmaceuticals Inc (ABOS) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
